The market for cancer drugs is an ever-roiling mix of shortages of low-cost generics and glut of high-priced brand pharmaceuticals.

This creates challenges for oncologists and oncology practices as they try to develop effective treatment plans for patients based on established drug therapies.

The answer, according to McKesson’s Grant Bogle, senior vice president, pharmaceutical and biotech solutions, is following treatment pathways that prioritize the efficacy, safety and cost of treatment regimens for specific types of cancer.